ALISO VIEJO, Calif. & SAN DIEGO--(BUSINESS WIRE)--Valeant Pharmaceuticals International (NYSE:VRX) and Metabasis Therapeutics, Inc. (Nasdaq:MBRX) today announced that their agreement with Schering-Plough Corporation (NYSE:SGP) for the assignment and license of development and commercial rights to pradefovir has closed. The close follows the early termination by the U.S. Federal Trade Commission of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976.
